Explore this article's sources with AI
Follow PeptideMethods on Google
Trevogrumab Preserved Lean Mass in COURAGE
A phase 2 trial found less lean-mass loss with trevogrumab during semaglutide treatment, while the garetosmab combination raised safety concerns.
Why we wrote this. This randomized trial directly tests an experimental strategy intended to reduce lean-mass loss during semaglutide treatment and reports an important safety contrast between antibody regimens.
In this article (5 sections)
In the phase 2 COURAGE trial, people receiving semaglutide lost less lean mass when trevogrumab was added. The benefit was larger when trevogrumab was combined with garetosmab, but that combination also produced substantially more serious adverse events and treatment discontinuations. The study therefore supports further research on GDF8 inhibition; it does not establish either experimental antibody as routine obesity treatment[1].
Lean mass is not the same as skeletal muscle, strength or physical function. COURAGE measured body composition, fat mass and bodyweight. Its report did not show that retaining more lean mass improved mobility, prevented disability or produced a net long-term health benefit[1].
How COURAGE tested the antibodies
COURAGE was a double-blind, placebo-controlled randomized trial at 60 US sites. It enrolled adults aged 18 to 80 with obesity and no history of diabetes. All groups in the reported obesity cohorts received semaglutide; randomization determined whether participants also received placebo, trevogrumab, or trevogrumab plus garetosmab. Trevogrumab blocks GDF8, also called myostatin, while garetosmab blocks activin A. Both signals can limit muscle growth[1][2].
Part A compared semaglutide plus placebo with semaglutide plus trevogrumab at 200 mg or 400 mg, and with semaglutide plus trevogrumab 400 mg plus garetosmab 10 mg/kg. Treatment lasted 26 weeks. Part A randomly assigned 605 participants, and 599 received at least one study-drug dose. Part B assigned 376 participants to semaglutide plus placebo or to semaglutide plus lower trevogrumab doses of 25 mg or 75 mg for 52 weeks[1]. These are descriptions of research arms, not dosing guidance.
The primary endpoints were percentage changes from baseline in lean mass, fat mass and bodyweight at week 26 in part A and week 52 in part B. Efficacy analyses included randomly assigned participants who received at least one study-drug dose and analyzed them according to assignment. Safety analyses used treatment actually received. Participants, principal investigators and site personnel were masked to assignment[1].
Lean-mass loss was smaller with trevogrumab
At week 26, lean mass declined by 6.6% with semaglutide plus placebo in part A. Compared with that group, the estimated treatment difference was 3.1 percentage points with trevogrumab 200 mg, 2.7 points with trevogrumab 400 mg, and 4.5 points with trevogrumab plus garetosmab. The confidence intervals were 1.9 to 4.3, 1.5 to 4.0, and 3.1 to 5.9 percentage points, respectively[1].
Part B supplied the longer follow-up. Lean mass declined by 7.3% at week 52 with semaglutide plus placebo. The difference was 1.5 percentage points with trevogrumab 25 mg, with a 95% confidence interval from -0.3 to 3.3. That interval included no difference. With trevogrumab 75 mg, the difference was 3.1 points, with a 95% confidence interval from 1.3 to 4.9[1]. The results suggest a dose-related signal, but they do not identify a clinically meaningful amount of lean-mass retention.
Fat and weight outcomes differed by regimen
In part A, fat mass fell by 15.6% with semaglutide plus placebo. The 400 mg trevogrumab group had 3.4 percentage points more fat-mass loss than placebo, while the trevogrumab-garetosmab combination had 11.7 points more. Other part A groups and all part B groups did not have significantly different fat-mass changes from semaglutide plus placebo[1].
Bodyweight fell by 10.6% with semaglutide plus placebo in part A. Only the antibody combination had a significantly different change, an additional 2.7 percentage points of weight loss. No part B group differed significantly from semaglutide plus placebo for bodyweight. These comparisons do not show whether a body-composition difference improves how a person feels or functions[1].
The combination raised a clear tolerability concern
Trevogrumab alone was reported as generally well tolerated, with a safety profile similar to semaglutide plus placebo. In contrast, 14 of 149 participants, or 9%, in the trevogrumab-garetosmab group had a serious adverse event, and 48 of 149, or 32%, discontinued treatment. Muscle spasms occurred in 61 of 149 participants, or 41%, in the combination group, compared with 23 of 299, or 8%, across the two higher-dose trevogrumab-only groups and seven of 151, or 5%, in the corresponding placebo group[1].
Gastrointestinal events were the most common adverse events and occurred at similar rates across groups. Two participants died during the study, both in the combination group. Investigators did not identify a causal association between treatment and either death. That assessment should not be rewritten as proof that treatment played no role, especially in a phase 2 trial not designed to resolve rare harms[1].
Limits and conflicts matter
The trial was funded by Regeneron Pharmaceuticals, the developer of both antibodies. Multiple authors were Regeneron employees and shareholders, and other investigators reported company support or additional industry relationships. Industry sponsorship does not erase randomized, masked comparisons, but it makes independent replication and access to complete methods and analyses important[1].
The indexed report was newly supplied by the publisher, and no PubMed Central full text was linked when this article was prepared. The abstract provides the principal body-composition estimates and selected safety counts, but it cannot answer every question about missing data, multiplicity, adjudication or subgroup consistency. The current registry confirms the randomized phase 2 design and sponsor, but it does not post tabulated results[1][2].
COURAGE provides controlled evidence that blocking GDF8 can reduce measured lean-mass loss during semaglutide treatment. It leaves a more important question open: whether the difference improves strength, mobility, metabolic health or quality of life enough to outweigh harms. Readers considering approved obesity treatment can review the broader semaglutide evidence overview, but the experimental antibodies should not be treated as available add-ons.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Did trevogrumab prevent all lean-mass loss with semaglutide?
No. Lean mass still declined. Trevogrumab groups had smaller declines than semaglutide plus placebo, with the clearer 52-week result seen at the 75 mg dose.
Did COURAGE measure muscle strength or physical function?
The reported primary endpoints were lean mass, fat mass and bodyweight. The publication abstract did not establish improved strength, mobility, disability or quality of life.
What happened when garetosmab was added?
The combination produced the largest lean-mass and fat-mass differences, but 9% had serious adverse events, 32% discontinued treatment and 41% reported muscle spasms.
Are trevogrumab and garetosmab approved add-ons to semaglutide?
No. COURAGE was a phase 2 study of experimental antibodies. Its body-composition findings require further study, including evidence about function, longer-term outcomes and safety.
Sources
No revisions yet. First published .